Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
机构：[1]Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University,Jinan, China[2]Department of Gynecologic Oncology, Qilu Hospital of Shandong University,Jinan, China[3]Department of Gynecologic Oncology, Chinese Academy ofMedical Sciences and Peking Union Medical College - National Cancer Center, CancerHospital, Beijing, China[4]Department of Gynecologic Oncology, Sun Yat-sen UniversityCancer Center, Guangzhou, Guangdong, China[5]Department of Gynecologic Oncology,Shanghai First People’s Hospital - Southern Division, Shanghai, China[6]Gynecologiconcology, Fudan University Shanghai Cancer Center, Shanghai, China[7]Gynecologicaltumor, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China[8]Department of Gynecologic Oncology, The Fourth Hospital of Hebei Medical University,Shijiazhuang, China河北医科大学第四医院[9]Department of Gynecologic Oncology, National CancerCenter/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy ofMedical Sciences and Peking Union Medical College, Beijing, China
第一作者机构：[1]Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University,Jinan, China
推荐引用方式(GB/T 7714)：
Song K.,Ma Y.,Li N.,et al.Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse[J].ANNALS OF ONCOLOGY.2022,33(7):S795-S795.doi:10.1016/j.annonc.2022.07.670.
APA：
Song, K.,Ma, Y.,Li, N.,Bu, H.,Huang, Y....&Wu, L..(2022).Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse.ANNALS OF ONCOLOGY,33,(7)
MLA：
Song, K.,et al."Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse".ANNALS OF ONCOLOGY 33..7(2022):S795-S795
医学